




VIRUSES CAUSING MENINGITIS, ENCEPHALITIS AND MENINGO-ENCEPHALITIS (MEMe)

SALVACION R. GATCHALIAN, M.D., FPPS, FPIDSP, FPSMID







EV 71

EMERGING VIRAL INFECTIONS (EID)



Diseases that infected new hosts

Spread into new geographic ranges

Altered characteristics of pathogenensis

Caused by agents not previously pathogeneic

Taylor and colleagues reviewed risk factors for human disease

- 1415 infectious organisms that are pathogenic to humans
- 175 emerging
 - 44% are viruses and prions
- Viruses have highest risk for emergence
- 80% had primary non-human source (zoonotic)
- 60% EID events are caused by zoonotic pathogens







EMERGING INFECTIOUS DISEASES



Highest concentration in US, Europe, Japan, and Southeast Asia

Predictive model identified "hotspots" due to zoonotic and vector-borne pathogens are in lower latitude developing countries (Tropical Africa, Latin America, Asia)

Olival and Daszak quantified viral EIDs affecting the nervous system

- 39% of viral EIDS cause severe neurologic symptoms, including encephalitis
- 10% rarely caused CNS symptoms







VIRAL INFECITONS OF THE CNS



Leads to meningitis, meningo-encephalitis and encephalitis

In practice, patients are diagnosed based on:

- Clinical manisfestations of brain dysfunction
- Laboratory or imaging evidence of inflammation

Acute life-threatening emergency

Requires prompt treatment







PATHOGENESIS



Direct invasion of brain tissue

- Acute encephalitis
- Virus culture from brain or evidence of virus on histologic exam
- Occur as extension of viral meningitis, 2º to viremia, retrograde spread via peripheral nerves (rabies, HSV)

Provoke autoimmune response leading to acute disseminated encephalomyelitis (ADEM)

- Virus not detected or recovered from brain
- With history of illness 2-4 weeks prior to onset







POSSIBLE INFECTIOUS ETIOLOGIES OF MENINGOENCEPHALITIS

DIST	ASE SOCIETA
E C	
INFE	
TALIAN	THE PARTY OF THE P

Viruses	Bacteria
Herpes Simplex Type 1	Fungi
Herpes Simplex Type 2	Parasites
Enteroviruses (echovirus, parechovirus, coxsackievirus A and B, poliovirus, and the numbered enteroviruses)	
Varicella Zoster Virus	
Epstein-Barr Virus	
Cytomegalovirus	
Human herpesvirus 6	
HIV	
Arboviruses (LaCrosse Virus, West Nile Virus, St. Louis encephalitis virus, Eastern and Western equine encephalitis virus, Japanese encephalitis virus)	
Rabies Virus, I nfluenza Virus, Measles Virus, Mumps Virus, Rubella Virus, Murray Valley Encephalitis Virus, Nipah Virus, Hendra Virus, Tick-Borne Encephalitis Virus, Powassan Virus, Herpes B Virus, Hepatitis E Virus, Creutzfeldt-Jakob Disease	

EPIDEMIOLOGY of EV 71



Non-polio enterovirus

Major cause of encephalitis in children

78% in US occur Jun-Oct

HFMD (Hand Foot Mouth Disease) common in children

- Mild and self-limiting
- In Asia, epidemics reported severe cases with complications
- EV 71 cause of HFMD with high neurological disease and cardiopulmonary involvement







ENTEROVIRUS 71



Virulent neurotropic enterovirus

Mainly affects children < 5y

Transmitted by oral-fecal-route, direct contacts, saliva, fluids

Responsible of Hand, Foot and Mouth disease (HFMD)

- Usually benign and self-limiting:
 - Fever, sore throat, general malaise, painfull sore mouth/throat, rash (+blisters)
 hands and feet (see next slide1)
- Epidemic (seasonal): social burden, scholar and parents distress, school closures
- EV71 is responsible of 70-80% of HFMD and of most of serious cases (Coxsackie A responsible of most of remaining cases of HFMD majority of those being CA16)







ENTEROVIRUS 71



With EV71 possible (rare) serious complications :encephalitis, meningitis, acute flaccid paralysis or cardiac and pulmonary complications and deaths in children (see next slide2)

eg (Chang LY et al JAMA 2004): in 2001-2002 in an hospital in Taiwan 183 children were identified with infection with EV71:

- 11 (6%) were asymptomatic
- 133 (73%) had uncomplicated illness (HFMD)
- 39 (21%) had complicated syndrome: CNS and cardiopulmonary failure
 - 13 (7%) long term sequela
 - 10 (5%) died (note: 87 adults from the same hospital were uneventfully affected)



















EV 71 was first identified in US California in 1969 (encephalitis in a child)

Epidemics with serious neurological disorders occurred in Bulgaria, Hungary in the seventies

- China:
 - No epidemics 1999-2006 but small sporadic inland or coastal outbreaks with (for Shenzhen) a few neurological cases but no fatalities reported
 - 17 deaths and 80,000 cases in 2007
 - 44 deaths and 176,000 infections in 2008 (to date): media coverage









Continued....

- Singapore (mid year 2008: 4,839 400 inhabitants; 671 300<14y)
 - Almost annual outbreak (see slide) and increasing prevalence:
 - 6403 cases in 2004; 15257 in 2005, 15299 in 2006, 20012 in 2007, 29686 cases in 2008 with 2 encephalitis and 1 death in August 08 (first since 2000-2001)¹
 - 9649 cases in 2009 (up to 27 June)²
 - The predominant strain isolated during the epidemic period was CA16 in 2005 and 2007, and EV71 in 2006 (20.5%) and 2008 (33.2%)³







- 1. Weekly Infectious Disease Bulletin. Vol. 5 No. 53 2008. Ministry of Health, Singapore.
- 2. Weekly Infectious Disease Bulletin. Vol. 6 No. 25 2009. Ministry of Health, Singapore.
- 3. Epidemiological News Bulletin. Oct-Dec 2008 Vol. 34 No. 4. Ministry of Health, Singapore.



Continued....

- Taiwan:
 - 78 deaths in 1998 (405 severe complications and 1.5M children affected)¹
 - almost annual outbreaks
 - More than 200,000 cases in 2008 (to date)?: large media coverage
 - In 2008, 344 cases of EV71 infection with severe complication, including 12 deaths²
- Malaysia:
 - 5999 cases and 42 deaths in 1997, subsequent outbreak in 2000, 2002, 2005, and 2006³
 - 5,141 cases (5 deaths) in 2006³ (to be compared with 17,147 cases and one death for dengue fever)
- Vietnam:
 - 764 cases of HFMD in 2005, 173 with EV71 (51 with neurological disease and 3 deaths)4
 - 12 HFMD deaths, 2,800 cases in 2008 (May)⁵
 - Increase in cases of HFMD in 2009 (Apr)⁶
 - 1. Ho M et al. An epidemic of enterovirus 71 infection in Taiwan. New England Journal of Medicine 1999. 341(13):929-935.
 - 2. Taiwan domestic epidemic of infectious disease report. Jan 2009. Taiwan CDC.
 - 3. Communicable disease surveillance, Disease Control Division, Ministry of Health Malaysia. http://www.dph.gov.my/survelans/
 - 4. Phan VT et al. Epidemiologic and virologic investigation of hand, foot and mouth disease, southern Vietnam, 2005. *Emerging Infectious Disease*, 2007, 13(11):1733-1741
 - 5. The Jakata Post, http://www.thejakartapost.com/news/2008/05/23/vietnam-warns-hand-foot-and-mouth-disease-spreading-among-children.html
 - 6. National Travel Health Network and Centre. http://www.nathnac.org/pro/clinical_updates/hfmd 220409.htm










Continued....

- Hong Kong:
 - one monoplegia in 1987¹, one death in 2001²
 - only tenths of EV71 cases reported yearly 2004-2007: 35 cases in 2004, 8 cases in 2005, 16 cases in 2006, 12 in 2007³
 - 98 cases in 2008 including 8 cases with severe complications and 1 death³
 - 49 cases of HFMD (21 EV71 infection, including 1 case with severe complication and 1 death) In 2009 (up to 2nd Jul)³
- Korea: outbreak in 2000⁴
 - 1 death and 1 toddler left brain dead in 2009 (June)⁵



- 2. Ng DKK et al. First fatal case of enterovirus 71 infection in Hong Kong. Hong Kong Medical Journal 2001; 7(2):193-196
- 3. EV Scan (Week 27, 2009). Centre for Health Protection, Department of Health Hong Kong
- 4. Jee YM et al. Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Korea during 2000. Arch. Virol 2000;148:1735-1746.
- 5. The Korea Times. http://www.koreatimes.co.kr/www/news/nation/2009/06/113 46311.html







Taiwan 1998-2006



Table 1	Number of cases of severe	and fatal enterovirus	infections in Taiwan fr	om 1998 to 2006
---------	---------------------------	-----------------------	-------------------------	-----------------

Year	Number of severe cases	Number of fatal cases (severe case-fatality rate)	EV71 number (%) among the fatal cases
1998	405	78 (19%)	34 (44%)
1999	35	9 (26%)	1 (11%)
2000	291	41 (14%)	25 (61%)
2001	393	58 (15%)	27 (47%)
2002	162	30 (19%)	8 (27%)
2003	70	8 (11%)	4 (50%)
2004	50	5 (10%)	5 (100%)
2005	142	16 (11%)	7 (44%)
2006	11	0	0 `
Total	1559	245 (15.7%)	111 (45.3%)

Data from CDC, Taiwan.

Chang LY Enterovirus 71 in Taiwan. Pediatr Neonatol 2008;49(4):103-112







Hong Kong 2004-2008



Annual number of HFMD outbreaks and EV71 cases in Hong Kong

Year 年份	Number of HFMD institutional outbreaks (persons affected) 手足口病院舍爆發數目^ (受影響人數)	Number of EV71 cases 腸病毒 7 1型 個案數字	Number of EV71 cases with severe complication 有嚴重併發症的 腸病毒 7 1 型個案數字	Number of fatal cases 死亡個案數字
2004	159 (1046)	35	0	0
2005	90 (656)	8	0	0
2006	236 (1744)	16	1	0
2007	157 (1081)	12	0	0
2008	167 (967)	98	8	1

[^]Statistics on HFMD also includes herpangina 手足口病統計數字包括疱疹性咽峽炎

EV Scan (Week 27, 2009). Centre for Health Protection, Department of Health Hong Kong



















Figure 3. Distribution of Cases/Specimen by month









Chikungunya

Enterovirus Results (July-Dec 2012)



Results by Case	No. of cases	Percentage
ENTEROVIRUS POSITIVE	671	75 50/
	671	75.5%
EV-71 POSITIVE	22	3.3%
NEGATIVE	173	19.5%
NOT TESTED	45	5%
Grand Total	889	







EPIDEMIOLOGY OF JAPANESE B



One of leading cause of acute encephalopathy in the tropics

Worldwide, 50,000 cases

15,000 (30%) die

Mosquito-borne viral infection of the CNS (Culex tritaeniorrhynchus)

Neurotropic flavivirus

Transmitted among birds, pigs, and other vertebrate hosts by vector-borne mosquito, culex species

Humans dead end hosts and infected when encroach on enzoonotic cycle

Major public health problem in Asia







EPIDEMIOLOGY OF JAPANESE B



Mainly a disease of children in rural areas

Acute Case Fatality Rate 30%

50% survivors with neurologic sequelae

After monsoon rains, mosquito breed and as they increase in number, carriage also increases

Viremia is brief and titers low

Asia, infection occurs in children and early adulthood







EPIDEMIOLOGY OF CHIKUNGUNYA VIRUS



Acute febrile illness caused by arthropod-borne aphavirus, Family *Togaviridae Chikungunya virus* (CHIKV)

Recognized as a human pathogen during 1950s in Africa

Cases identified since then in Africa and Asia

Transmitted to humans via bite of infected Aedes species mosquito

Circulates in a sylvatic cycle between forest dwelling *Aedes* species mosquitoes and non-human primates

In urban centers of Africa and Asia, virus can circulate between mosquitoes and naive human similar ot dengue viruses







EPIDEMIOLOGY OF CHIKUNGUNYA VIRUS



2 main vectors:

- Aedes aegypti
- Aedes albopictus

Resurgence drawn global attention due:

- Explosive onset
- rapid spread
- high morbidity
- myriad of clinical manifestations

2006 onwards, emerged in non-endemic areas as important disease in returning travellers

- Sentinels
- Transporters
- Transmitters







EPIDEMIOLOGY OF CHIKUNGUNYA VIRUS



Displays secular, cyclical and seasonal trends

Epidemics are explosive outbreaks interspersed by periods of disappearance from several years to decades

- Reason unknown
- Humans are reservoir
- Interpandemics vertebrates (monkeys, rodents, birds)

No evidence of tranovarial transmission of CHIKV in mosquitoes

Vertical maternal-fetal transmission documented













ACTA MEDICA PHILIPPINA

Isolation of Chikungunya Virus in the Philippines

(Received February 10, 1969)

Lourdes E. Campos, M.D., M.P.H., Adelina San Juan, B.S. Hygiene,
Linda C. Cenabre, B.S. Hygiene
Department of Medical Microbiology, Institute of Hygiene
and Elena F. Almagro, B.S. Hygiene
Medical Research Laboratory
Department of Medicine, College of Medicine

SUMMARY

The isolation of 15 viral agents in suckling mice from 26 serum samples of cases charaterized by fever, rash and severe and lingering joint pains is presented. Eight hemagglutinating isolates were identified by hemagglutination-inhibition test. Seven of them were identified as chikungunya virus and one, a group B arbovirus, most probably a dengue virus. The immunologic responses noted in the patients confirm the identity of the isolates.

1st reported cluster in the Philippines in 1967.
 Testing confirmed presence of Chikungunya virus in the outbreak samples.








EPIDEMIOLOGIC AND HISTORIC CLUES TO THE ETIOLOGY OF ENCEPHALITIS IN CHILDREN



Epidemiologic Clues	Potential Etiologies
Age (0 to 28 days)	Infectious: CMV, HSV-2 or HSV-1 Rubella Virus
Season: Summer Late Summer/Fall Winter Infection in Horses, birds Blood Transfusion or Transplant recipient Immunodeficiency	Enterovirus, Free living amebae Arbovirus Postinfectious encephalitis in countries with low rates of MMR immunization Arbovirus CMV, EBV, HIV, rabies, tick-borne encephalitis, WNV CMV, enterovirus, HHV6, HSV, VZV, WNV
Historical Clues	
Rash: Vesicular Hand, foot, mouth Erythematous macules and papules with cephalocaudad spread Maculopapular Maculopapular/petechial begins on ankles and wrists	HSV, VZV, enterovirus (Hand, foot, and mouth disease), herpes B virus Enterovirus Measles WNV Rocky Mountain spotted fever
Exposures: Mosquitoes Ticks Animal bite/exposure (dog, bat, cat, birds, livestock, others) Blood transfusion or transplant recipient Recent Infectious Illness	Arbovirus Borrelia burgdorferi, Powasan virus, Rickettsia rickettsii, tick-borne encephalitis Rabies, arboviruses, cat scratch disease, Q fever CMV, EBV, HIV, rabies, tick-borne encephalitis, WNV ADEM
Recreational Activity: Swimming / Spelunking / Sexual Activity	Enteroviruses, free-living amebae / Rabies / HIV

TRAVEL HISTORY AND POSSIBLE ETIOLOGIC AGENT(S) OF VIRAL ENCEPHALITIS



Travel	Possible Infectious Agent(s)
Africa	Rabies, West Nile Virus, Plasmodium Falciparum, Trypanasoma brucei gambiense, T. Brucei rhodesiense
Australia	Murray Valley encephalitis virus, Japanese encephalitis virus, Hendra virus
Central America	Rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan encephalitis virus, St. Louis encephalitis virus, Rickettsia rickettsii, P. Falciparum, Taenia solium
Europe	West Nile Virus, Tick-borne encephalitis virus, Borrelia burgdorferi, Anaplasma phagocytophilum
India, Nepal	Rabies Virus, Japanese Encephalitis virus, P. Falciparum
Middle East	West Nile Virus, P. Falciparum
Russia	Tick-Borne encephalitis virus
South America	Rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan encephalitis virus, St. Louis encephalitis virus, Rickettsia rickettsii, Bartonella bacilliformis (Andres mountain) . Falciparum, Taenia solium
Southeast Asia, China, Pacific Rim	Japanese Encephalitis Virus, Tickborne Encephalitis Virus, Nipah Virus, P. Falciparum, Gnathostoma species, Taenia solium

CLINICAL MANIFESTATIONS



Encephalitis causes neurologic dysfunction with broad range of presentation

Clinical manifestation vary

- Portions of CNS affected
- Pathogenic agent
- Host factors
 - Clinical features of viral infection at specific sites of CNS







http://www.uptodate.com/contents/acute-viral-encephalitis-in -children-and-adolescents 2/18/2013

CLINICAL CLUES FOR VIRAL INFECTIONS OF THE CNS IN CHILDREN



Etiology	Frequency of Meningitis vs Encephalitis		Potential Clues
	Meningitis	Encephalitis	
Enteroviruses (EV71)	Common	Rare	Rash - popular & petechial with diffuse erythema in trunk and limbs.
			Faucial rush of blisters with haloes of inflammation
			Truncial ataxia, myoclonus, intertion tremor
			Impaired consiousness
			Pulmonary edema
			Pharyngitis, croup, bronchiolitis, pneumonia







CLINICAL CLUES FOR VIRAL INFECTIONS OF THE CNS IN CHILDREN



Etiology	Frequency of Meningitis vs Encephalitis		Potential Clues	
	Meningitis	Encephalitis		
Japanese B	rare	common	Non specific febrile illness (coryza, diarrhea, rigor), headache, vomiting	
			Reduced level of conciousness	
			convulsion	
			Abnormal behavior (older children and adults)	
			Dull, flat mask-like facies with wide unbinking eys, tremor, generalized hypertonia, rigidity	
			Accute flaccid paralysis	







CLINICAL CLUES FOR VIRAL INFECTIONS OF THE CNS IN CHILDREN



Etiology	Frequency of Meningitis vs Encephalitis		Potential Clues
	Meningitis	Encephalitis	
Chikungunya Fever	Not common	Not common	Abrupt, sudden onset of fever
			Arthralgias, myalgia
			Skin rash
			Headache, throat discomfort, abdominal pain, constipation
			Conjunctival suffusion, persistent conjunctivitis, cervical or generalized lymphadenopathy









Percentage of CHIKV among DEN Negative pediatric patients from 2009-2010 in 3 sentinel sites (N=216)













RITM EXPERIENCE IN 2012



- Brought about by the outbreaks in 2011, RITM through the support of DOH, has begun providing IgM testing services for Chikungunya
- A total of 990 referrals for Chikungunya IgM Testing were received at the NRL for Dengue and other Arboviruses (this includes samples from clusters of cases as well as routine diagnostic samples)

Chikungunya IgM Testing 2012						
Positive Equivocal Negative Total						
562 (56.7%)	67 (6.2%)	367 (37.1%)	990			







CAPTURED THROUGH MEASLES SURVEILLANCE



- From June-September 2012, cases in several regions with fever and rash were investigated under the measles surveillance.
- Cases had pronounced joint symptoms/body aches and occurred generally in the more elderly population.
- Out of 43 measles negative cases, 30 (70%) were positive for CHIKV IgM, 5 (12%) were equivocal, and 8 (18%) negative.

Chikungunya IgM Testing of Measles Negative Cases			
Positive	Equivocal	Negative	Total
30 (70%)	5 (12%)	8 (18%)	43








RITM EXPERIENCE IN 2012

(Distribution over Space and Time)






RITM EXPERIENCE IN 2012

(Distribution across Regions)






RITM EXPERIENCE IN 2012

(Age Distribution)






RITM EXPERIENCE IN 2012

(Sex distribution)





COMPARISON BETWEEN CHIKUNGUNYA AND DENGUE FEVER



	CHIKUNGUNYA	DENGUE
Fever	Common	Common
Rash	D1-D4	D5-D7
Retroorbital pain	Rare	Common
Arthralgia	Constant	Rare
Arthritis	Common, edematous	Absent
Myalgia	Common	Common
Tenosynovitis	Common	Absent
Hypotension	Possible	Common, D5-D7
Minor Bleeding	Rare	Common, D5-D7
Outcome	Persistent arthralgia for months to years, M2-M3 Possible Raynaud/tenosynovitis	Possible Fatigue for weeks
Thrombocytopenia	Early and mild	Delayed and possibly deep

ChikV v DENV LABORATORY PROFILE



Laboratory features	Chikungunya virus infection	Dengue virus infection
Leukopenia	++	+++
Neutropenia	+	+++
Lymphopenia	+++	++
Elevated hematocrit	-	++
Thrombocytopenia	+	+++

Staples et al Clin Inf Dis Sept 2009; 49: 942-8







Manifestations of Chikungunya have an Acute and a Chronic Component



Acute (2-10 days)





Edematous rash







Myalgia

Chronic (months to years)





Inflammatory osteoarthritis



Swollen and stiff joints

DIAGNOSIS



Requires rapid, comprehensive and systematic approach

Early ID of cause crucial for management and prognosis

Evaluation of child with altered brain function

- Assessement of airway
- Breathing
- Circulation

Priorities are stabilization of cardio-respiratory status, management of seizures









History

Symptoms: fever; depressed or altered level of consciousness; lethargy; personality change; emotional lability; seazure; ataxia

Travel

Exposure (animals, insects, freshwater swimming, toxins

Immunizations

Immune status

Physical findings

Vital signs and general examination

Neurologic examination, particularly for focal findings and GCS









Laboratory studies

Screening laboratories: CBC; glucose; electrolytes; BUN; creatinine; ammonia; blood pH; blood cultures; LFTs; urinalysis; urine drug screen; save a sample of acute serum

Lumbar puncture; perform emergently, often after neuroimagingif a focal lesion is suspected; obtain opening pressure when clinically feasible; send CSF for cell count/differential, glucose, protein, bacterial culture, HSV PCR, enterovirus PCR; save a sample PCF

Other laboratory tests to consider: Influenza testing during influenza season; tests for toxic metabolic encephalopathy and inborn errors of metabolism (see text); antibody studies for NMDAR and VGKC (see text)

Ancillary studies

Neuroimaging: MRI preferred, but CT if MRI not promptly available, impractical, or cannot be performed

EEG: as soon as is feasible (for evidence of encephalitis or nonconvulsive seizure)









Treatment

Stabilization

Support airway, breathing and circulation

Endotracheal intubation for GCS \leq 8 or compromised airway

Fluid resuscitation with normal saline (20 mL/kg, initial bolus) for sings of shock

Obtain rapid glucose; treat if hypoglycemic with 2.5mL/kg of 10% dextrose solution

Treat seazures with lorazepam (0.1 mg/kg intravenously) or equivalent benzodiazepine









Treatment

Empiric therapy (initial dose)*

Treat for influenza, as indicated, during influenza season with oseltamivir (0 to 3 months: 12 mg orally; 4 to 5 months: 17 mg orally; 6 to 11 months; 24 mg orally; \geq 12 months and \leq 15 kg: 30 mg orally; 15 to 23 kg: 45 mg orally; 23 to 40 kg: 60 mg orally; \geq 40 kg and/or \geq 12 years old: 75 mg orally)

Administer acyclovir (> 29 days to < 12 years: 20 mg/kg intravenously; ≥ 12 years: 10 mg/kg intravenously) to all patient without a specific diagnosis other than HSV

Treat for bacterial meningitis as indicated (eg vancomycin [15 mg/kg intravenously] **plus either** ceftriaxone [50 mg/kg intravenously] or cefotaxime [100 mg/kg intravenously)

Treat for rickettsial infection (eg, Rocky Mountain spotted fever, Q fever) or ehrlichiosis in children at risk (doxycycline [2.2 mg/kg intravenously or orally])





PREVENTION AND CONTROL



EV 71

Vaccine is currently being develop

Chikungunya

No vaccine available

Japanese B

- Vaccine available
 - Live-attenuated
 - Inactivated
 - Routinely administered in Thailand, Malaysia











THANK YOU